Synthesis and assessment of analgesic activity of a new 5-butyl-1,2-diphenyl-6-oxo-1,6-dihydropyrimidin-4-olate sodium


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Aim. 5-butyl-1,2-diphenyl-6-oxo-1,6-dihydropyrimidine-4-sodium olate synthesis (test compound, target compound) and its acute toxicity, analgesic activity in silico and in vivo evaluation. Material and methods. The target compound was obtained by the interaction of 5-butyl-6-hydroxy-2,3-diphenylpyrimidin-4 (3H) -OH radicals and an sodium hydroxide aqueous solution equimolar amount. The structure was proved by NMR 1H and 13C spectroscopy. The test compound acute toxicity prediction was carried out using the GUSAR software. Acute toxicity in vivo was determined in white outbred male mice. Biological activity computer screening was performed using the PASS program located on a web service freely accessible via the Internet. For the analgesic activity experimental assessment, two models were used: tail-flicking ofthe tail from heat radiation and acetic acid cramps. Results. Sodium 5-butyl-1,2-diphenyl-6-oxo-1,6-dihydropyrimidine-4-olate was synthesized in quantitative yield. The structure is proved using 1H and 13C NMR spectroscopy. The acute toxicity predicted and experimental data allow to classify the compound under study as moderately hazardous. During the biological activity screening with the PASS program help, data on the alleged analgesic effect we re obtained. The analgesic activity study in vivo showed that the target compound hasa pronounced effect. Conclusion. A new compound, 5-butyl-1,2-diphenyl-6-oxo-1,6-dihydropyrimidine-4-sodium olate, was synthesized. Its structure has been proven using modern physicochemical analysis methods. The computer modelling results made it possible to determine the toxicity class and potential biological activity. With the experimental pharmacological studies help, it was proved that the studied compound has a toxicity low level and shows pronounced analgesic activity.

全文:

受限制的访问

作者简介

E. Kuvaeva

Saint-Petersburg State Chemical and Pharmaceutical University

Email: elena.kuvaeva@pharminnotech.com
Ph.D.(Pharm.), Associate Professor, Department of Organic Chemistry

D. Kolesnik

Saint-Petersburg State Chemical and Pharmaceutical University

Email: denis.kolesnik@spcpu.ru
Post-graduate Student

P. Levshukova

Saint-Petersburg State Chemical and Pharmaceutical University

Email: levshukova.polina@pharminnotech.com
Student

D. Ivkin

Saint-Petersburg State Chemical and Pharmaceutical University

Email: dmitry.ivkin@pharminnotech.com
Ph.D.(Biol,), Associate Professor, Department of Pharmacology and Clinical Pharmacology

I. Yakovlev

Saint-Petersburg State Chemical and Pharmaceutical University

Email: igor.yakovlev@pharminnotech.com
Dr.Sc. (Chem.), Professor, Head of the Department of Organic Chemistry

参考

  1. Государственный реестр лекарственных средств [справочная система]. URL: grls.rosminzdrav.ru (дата обращения 24.01.2021).
  2. Патент 2738605 С1 РФ. 5-Замещённые-6-гидрокси-2,3-дифенилпиримидин-4-(ЗН)-оны и способ их получения. ДА. Колесник, Е.В. Kyeaeea, T.Л. Семакова, О.Ю. Стрелова, И.П. Яковлев. 2020.
  3. GUSAR V. 2011.1: система моделирования острой токсичности [для моделирования]. А. Захаров, В. Поройков. Москва: 2011. (Электронная дистрибьюция).
  4. Миронов А.Н. Руководство по проведению доклинических исследований лекарственных средств. Часть первая. М.: Гриф и К, 2012. 944 с.
  5. STATISTICA 7.0: система статистического анализа [для статистического анализа]. «StatSoft» - Америка: 1984. (Электронная дистрибьюция).
  6. PASS Online. Way2Drug: [веб-ресурс]. Москва.ХЖЬ: www.way2drug.com/PASSOnline (дата обращения 24.01.2021).

补充文件

附件文件
动作
1. JATS XML

版权所有 © Russkiy Vrach Publishing House, 2021
##common.cookie##